Trulicity and Wegovy are not the same medication. They belong to the same drug class, GLP-1 receptor agonists, and they work in a similar way, but they contain different active ingredients, are made by different companies, and are approved for different primary purposes. The active ingredient in Trulicity is dulaglutide, while Wegovy contains semaglutide.
How They Work
Both Trulicity and Wegovy mimic a natural gut hormone called GLP-1 that your body releases after eating. This hormone signals your brain to feel full, slows down how fast food leaves your stomach, and helps regulate blood sugar by triggering insulin release when levels are high. Because both drugs target the same receptor, their overall effects overlap considerably, which is why people often assume they’re interchangeable.
The key difference is molecular. Dulaglutide (Trulicity) and semaglutide (Wegovy) are engineered slightly differently, which affects how potent they are, how long they last in the body, and how much weight loss or blood sugar control they produce at their respective doses. Both are injected once a week.
Different Approved Uses
Trulicity is FDA-approved primarily for type 2 diabetes management. It helps lower blood sugar and has also been shown to reduce cardiovascular risk in people with diabetes. It is manufactured by Eli Lilly.
Wegovy is FDA-approved specifically for chronic weight management in adults with obesity or overweight who have at least one weight-related health condition. It’s also approved for reducing cardiovascular risk. Novo Nordisk manufactures Wegovy. Notably, semaglutide also exists under the brand name Ozempic, which is the diabetes-focused version of the same molecule. Wegovy simply uses higher doses of semaglutide optimized for weight loss.
Weight Loss and Cardiovascular Differences
Semaglutide, the ingredient in Wegovy, appears to be more effective than dulaglutide for both weight loss and heart protection. A real-world study comparing nearly 30,000 semaglutide users against the same number of dulaglutide users found that semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, and death) by 23% compared to dulaglutide. It also lowered the risk of death from any cause by 26%.
For weight loss specifically, clinical trials have consistently shown semaglutide produces greater reductions in body weight than dulaglutide at their respective maximum doses. This is one reason Wegovy became the more prominent name in the weight loss conversation, even though Trulicity can also cause some weight loss as a secondary effect.
Dosing Schedules
Both medications are taken as a once-weekly injection, but they follow different dosing paths.
Wegovy starts at a low dose of 0.25 mg per week, increasing every four weeks to let your body adjust. The recommended maintenance dose for weight loss in adults is 2.4 mg, though doses up to 7.2 mg are available when additional weight reduction is needed. Wegovy also now comes in a daily pill form, starting at 1.5 mg and titrating up to a 25 mg maintenance dose over several months.
Trulicity follows a similar gradual approach but with different dose levels. Most people start at 0.75 mg weekly, with a maximum dose of 4.5 mg. The ramp-up period exists for the same reason: to minimize the gastrointestinal side effects that come with this drug class.
Side Effects
The side effect profiles are similar because both drugs work through the same mechanism, but the specific patterns differ. Based on user-reported data from Drugs.com reviews, Trulicity users more frequently report nausea (about 40% vs. 31% for Wegovy), diarrhea (24% vs. 10%), and vomiting (18% vs. 11%). Wegovy users, on the other hand, report constipation more often (16% vs. less common with Trulicity) along with heartburn.
These numbers come from patient self-reports rather than controlled clinical trials, so they reflect real-world experience more than precise clinical rates. Still, the overall picture is clear: both drugs cause significant GI discomfort, especially during the dose escalation period. Most people find these effects lessen after the first few months as the body adjusts.
Storage Requirements
Both medications come as prefilled injection pens that need refrigeration between 36°F and 46°F. Wegovy pens can be kept at room temperature (up to 86°F) for a maximum of 28 days, which is useful for travel. You should discard a Wegovy pen if it has been frozen, exposed to temperatures above 86°F, left in direct light, or kept out of the fridge for longer than 28 days. Trulicity follows similar cold-chain storage rules, with its own room-temperature window of up to 14 days.
Availability and Cost
Trulicity has been on the market since 2014, and as of early 2026, Eli Lilly reports that supply is available, though some pharmacies may still have intermittent stock issues depending on location. Wegovy experienced significant supply shortages after its 2021 launch due to overwhelming demand, though availability has gradually improved.
Insurance coverage differs substantially between the two. Because Trulicity is classified as a diabetes drug, it’s more commonly covered under diabetes-related pharmacy benefits. Wegovy, labeled as a weight management drug, often faces stricter coverage rules. Many insurance plans exclude weight loss medications entirely, making Wegovy significantly more expensive out of pocket for people without coverage. If your doctor is considering one of these medications, which one your insurance will cover may end up being the deciding factor.
Can You Switch Between Them?
Because they contain different active ingredients, switching from Trulicity to Wegovy (or vice versa) isn’t a simple dose-for-dose swap. Your prescriber will typically restart you at a low dose of the new medication and titrate up again to minimize side effects. Some people switch because they want stronger weight loss effects from semaglutide, while others move to dulaglutide if they experience side effects they can’t tolerate on semaglutide. The transition usually takes several weeks as you work back up to a therapeutic dose.